Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.

Child Diagnosis Macrolide-resistant Mycoplasma pneumoniae Recommendation Treatment

Journal

World journal of pediatrics : WJP

ISSN: 1867-0687

Titre abrégé: World J Pediatr

Pays: Switzerland

ID NLM: 101278599

Informations de publication

Date de publication:
14 Aug 2024

Historique:

received: 26 04 2024

accepted: 15 07 2024

medline: 15 8 2024

pubmed: 15 8 2024

entrez: 14 8 2024

Statut: aheadofprint

Résumé

Mycoplasma pneumoniae (M. pneumoniae) is a significant contributor to community-acquired pneumonia among children. Since 1968, when a strain of M. pneumoniae resistant to macrolide antibiotics was initially reported in Japan, macrolide-resistant M. pneumoniae (MRMP) has been documented in many countries worldwide, with varying incidence rates. MRMP infections lead to a poor response to macrolide antibiotics, frequently resulting in prolonged fever, extended antibiotic treatment, increased hospitalization, intensive care unit admissions, and a significantly higher proportion of patients receiving glucocorticoids or second-line antibiotics. Since 2000, the global incidence of MRMP has gradually increased, especially in East Asia, which has posed a serious challenge to the treatment of M. pneumoniae infections in children and attracted widespread attention from pediatricians. However, there is still no global consensus on the diagnosis and treatment of MRMP in children. We organized 29 Chinese experts majoring in pediatric pulmonology and epidemiology to write the world's first consensus on the diagnosis and treatment of pediatric MRMP pneumonia, based on evidence collection. The evidence searches and reviews were conducted using electronic databases, including PubMed, Embase, Web of Science, CNKI, Medline, and the Cochrane Library. We used variations in terms for "macrolide-resistant", "Mycoplasma pneumoniae", "MP", "M. pneumoniae", "pneumonia", "MRMP", "lower respiratory tract infection", "Mycoplasma pneumoniae infection", "children", and "pediatric". Epidemiology, pathogenesis, clinical manifestations, early identification, laboratory examination, principles of antibiotic use, application of glucocorticoids and intravenous immunoglobulin, and precautions for bronchoscopy are highlighted. Early and rapid identification of gene mutations associated with MRMP is now available by polymerase chain reaction and fluorescent probe techniques in respiratory specimens. Although the resistance rate to macrolide remains high, it is fortunate that M. pneumoniae still maintains good in vitro sensitivity to second-line antibiotics such as tetracyclines and quinolones, making them an effective treatment option for patients with initial treatment failure caused by macrolide antibiotics. This consensus, based on international and national scientific evidence, provides scientific guidance for the diagnosis and treatment of MRMP in children. Further studies on tetracycline and quinolone drugs in children are urgently needed to evaluate their effects on the growth and development. Additionally, developing an antibiotic rotation treatment strategy is necessary to reduce the prevalence of MRMP strains.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

We organized 29 Chinese experts majoring in pediatric pulmonology and epidemiology to write the world's first consensus on the diagnosis and treatment of pediatric MRMP pneumonia, based on evidence collection. The evidence searches and reviews were conducted using electronic databases, including PubMed, Embase, Web of Science, CNKI, Medline, and the Cochrane Library. We used variations in terms for "macrolide-resistant", "Mycoplasma pneumoniae", "MP", "M. pneumoniae", "pneumonia", "MRMP", "lower respiratory tract infection", "Mycoplasma pneumoniae infection", "children", and "pediatric".

RESULTS RESULTS

Epidemiology, pathogenesis, clinical manifestations, early identification, laboratory examination, principles of antibiotic use, application of glucocorticoids and intravenous immunoglobulin, and precautions for bronchoscopy are highlighted. Early and rapid identification of gene mutations associated with MRMP is now available by polymerase chain reaction and fluorescent probe techniques in respiratory specimens. Although the resistance rate to macrolide remains high, it is fortunate that M. pneumoniae still maintains good in vitro sensitivity to second-line antibiotics such as tetracyclines and quinolones, making them an effective treatment option for patients with initial treatment failure caused by macrolide antibiotics.

CONCLUSIONS CONCLUSIONS

This consensus, based on international and national scientific evidence, provides scientific guidance for the diagnosis and treatment of MRMP in children. Further studies on tetracycline and quinolone drugs in children are urgently needed to evaluate their effects on the growth and development. Additionally, developing an antibiotic rotation treatment strategy is necessary to reduce the prevalence of MRMP strains.

Identifiants

DOI: 10.1007/s12519-024-00831-0 PMID: 39143259

pubmed: 39143259

doi: 10.1007/s12519-024-00831-0

pii: 10.1007/s12519-024-00831-0

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Subventions

Organisme : Key R & D Projects of Zhejiang Province

ID : 2023C03009

Organisme : Key R & D Projects of Zhejiang Province

ID : 2024C03177

Informations de copyright

Références

Kim K, Jung S, Kim M, Park S, Yang HJ, Lee E. Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis. JAMA Netw Open. 2022;5:e2220949.

pubmed: 35816304 pmcid: 9274321 doi: 10.1001/jamanetworkopen.2022.20949

Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311:376–80.

pubmed: 7640549 pmcid: 2550437 doi: 10.1136/bmj.311.7001.376

Schünemann H, Brozek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group; 2013.

Zhao F, Liu G, Wu J, Cao B, Tao X, He L, et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother. 2013;57:1521–3.

pubmed: 23263003 pmcid: 3591905 doi: 10.1128/AAC.02060-12

Qu J, Chen S, Bao F, Gu L, Cao B. Molecular characterization and analysis of Mycoplasma pneumoniae among patients of all ages with community-acquired pneumonia during an epidemic in China. Int J Infect Dis. 2019;83:26–31.

pubmed: 30926541 doi: 10.1016/j.ijid.2019.03.028

Wang YC, Wu XR, Liu F, Yin QQ, Li JQ, Wang YH, et al. Epidemiological characteristics and drug resistance of mycoplasma pneumonia infection in children hospitalized in Beijing from 2016 to 2019. Chin J Appl Clin Pediatr. 2022;37:1082–5 (in Chinese).

Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis. 2010;67:355–8.

pubmed: 20638604 doi: 10.1016/j.diagmicrobio.2010.03.004

Jiang TT, Sun L, Wang TY, Qi H, Tang H, Wang YC, et al. The clinical significance of macrolide resistance in pediatric Mycoplasma pneumoniae infection during COVID-19 pandemic. Front Cell Infect Microbiol. 2023;13:1181402.

pubmed: 37249975 pmcid: 10213390 doi: 10.3389/fcimb.2023.1181402

Morozumi M, Tajima T, Sakuma M, Shouji M, Meguro H, Saito K, et al. Sequence type changes associated with decreasing macrolide-resistant Mycoplasma pneumoniae, Japan. Emerg Infect Dis. 2020;26:2210–3.

pubmed: 32818419 pmcid: 7454074 doi: 10.3201/eid2609.191575

Tanaka T, Oishi T, Miyata I, Wakabayashi S, Kono M, Ono S, et al. Macrolide-resistant Mycoplasma pneumoniae Infection, Japan, 2008–2015. Emerg Infect Dis. 2017;23:1703–6.

pubmed: 28930026 pmcid: 5621555 doi: 10.3201/eid2310.170106

Nakamura Y, Oishi T, Kaneko K, Kenri T, Tanaka T, Wakabayashi S, et al. Recent acute reduction in macrolide-resistant Mycoplasma pneumoniae infections among Japanese children. J Infect Chemother. 2021;27:271–6.

pubmed: 33500118 doi: 10.1016/j.jiac.2020.10.007

Tsai TA, Tsai CK, Kuo KC, Yu HR. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J Microbiol Immunol Infect. 2021;54:557–65.

pubmed: 33268306 doi: 10.1016/j.jmii.2020.10.002

Chang CH, Tsai CK, Tsai TA, Wang SC, Lee YC, Tsai CM, et al. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Southern Taiwan, China. Pediatr Neonatol. 2021;62:536–42.

pubmed: 34147432 doi: 10.1016/j.pedneo.2021.05.017

Wang G, Wu P, Tang R, Zhang W. Global prevalence of resistance to macrolides in Mycoplasma pneumoniae: a systematic review and meta-analysis. J Antimicrob Chemother. 2022;77:2353–63.

pubmed: 35678262 doi: 10.1093/jac/dkac170

Lee JK, Choi YY, Sohn YJ, Kim KM, Kim YK, Han MS, et al. Persistent high macrolide resistance rate and increase of macrolide-resistant ST14 strains among Mycoplasma pneumoniae in South Korea, 2019–2020. J Microbiol Immunol Infect. 2022;55:910–6.

pubmed: 34475003 doi: 10.1016/j.jmii.2021.07.011

Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J. 2012;31:409–11.

pubmed: 22209916 doi: 10.1097/INF.0b013e318247f3e0

Zheng X, Lee S, Selvarangan R, Qin X, Tang YW, Stiles J, et al. Macrolide-resistant Mycoplasma pneumoniae, United States. Emerg Infect Dis. 2015;21:1470–2.

pubmed: 26196107 pmcid: 4517703 doi: 10.3201/eid2108.150273

Waites KB, Ratliff A, Crabb DM, Xiao L, Qin X, Selvarangan R, et al. Macrolide-resistant Mycoplasma pneumoniae in the United States as determined from a national surveillance program. J Clin Microbiol. 2019;57:e00968–1019.

pubmed: 31484701 pmcid: 6813023 doi: 10.1128/JCM.00968-19

Rothstein TE, Cunningham SA, Rieke RA, Mainella JM, Mutchler MM, Patel R. Macrolide resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021. Antimicrob Agents Chemother. 2022;66:e0243221.

pubmed: 35311520 doi: 10.1128/aac.02432-21

Chironna M, Sallustio A, Esposito S, Perulli M, Chinellato I, Di Bari C, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother. 2011;66:734–7.

pubmed: 21393214 doi: 10.1093/jac/dkr003

Rivaya B, Jordana-Lluch E, Fernandez-Rivas G, Molinos S, Campos R, Mendez-Hernandez M, et al. Macrolide resistance and molecular typing of Mycoplasma pneumoniae infections during a 4 year period in Spain. J Antimicrob Chemother. 2020;75:2752–9.

pubmed: 32653897 pmcid: 7678890 doi: 10.1093/jac/dkaa256

Loconsole D, De Robertis AL, Sallustio A, Centrone F, Morcavallo C, Campanella S, et al. Update on the epidemiology of macrolide-resistant Mycoplasma pneumoniae in Europe: a systematic review. Infect Dis Rep. 2021;13:811–20.

pubmed: 34562998 pmcid: 8482213 doi: 10.3390/idr13030073

Lanata MM, Wang H, Everhart K, Moore-Clingenpeel M, Ramilo O, Leber A. Macrolide-resistant Mycoplasma pneumoniae infections in children, Ohio, USA. Emerg Infect Dis. 2021;27:1588–97.

pubmed: 34013867 pmcid: 8153876 doi: 10.3201/eid2706.203206

Yang HJ. Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr. 2019;62:199–205.

pubmed: 30999732 pmcid: 6584239 doi: 10.3345/kjp.2018.07367

Zhang Y, Zhou Y, Li S, Yang D, Wu X, Chen Z. The clinical characteristics and predictors of refractory Mycoplasma pneumoniae pneumonia in children. PLoS One. 2016;11:e0156465.

pubmed: 27227519 pmcid: 4882022 doi: 10.1371/journal.pone.0156465

Zhao S, Musa SS, Qin J, He D. Phase-shifting of the transmissibility of macrolide-sensitive and resistant Mycoplasma pneumoniae epidemics in Hong Kong, from 2015 to 2018. Int J Infect Dis. 2019;81:251–3.

pubmed: 30822543 doi: 10.1016/j.ijid.2019.02.030

Chen YC, Hsu WY, Chang TH. Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumonia. Emerg Infect Dis. 2020;26:1382–91.

pubmed: 32568052 pmcid: 7323531 doi: 10.3201/eid2607.200017

Zhang WZ, Zhang SJ, Wang QY, Li YD, Jing HB, Hu GY, et al. Outbreak of macrolide-resistant Mycoplasma pneumoniae in a primary school in Beijing, China in 2018. BMC Infect Dis. 2019;19:871.

pubmed: 31640591 pmcid: 6805422 doi: 10.1186/s12879-019-4473-6

Suzuki Y, Itagaki T, Seto J, Kaneko A, Abiko C, Mizuta K, et al. Community outbreak of macrolide-resistant Mycoplasma pneumoniae in Yamagata, Japan in 2009. Pediatr Infect Dis J. 2013;32:237–40.

pubmed: 23114374 doi: 10.1097/INF.0b013e31827aa7bd

Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30:747–809.

pubmed: 28539503 pmcid: 5475226 doi: 10.1128/CMR.00114-16

Wang Y, Ye Q, Yang D, Ni Z, Chen Z. Study of two separate types of macrolide-resistant Mycoplasma pneumoniae outbreaks. Antimicrob Agents Chemother. 2016;60:4310–4.

pubmed: 27161643 pmcid: 4914620 doi: 10.1128/AAC.00198-16

Niitu Y, Hasegawa S, Suetake T, Kubota H, Komatsu S, Horikawa M. Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J Pediatr. 1970;76:438–43.

pubmed: 5413664 doi: 10.1016/S0022-3476(70)80485-1

Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri T, et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol. 2001;45:617–20.

pubmed: 11592636 doi: 10.1111/j.1348-0421.2001.tb01293.x

Bebear CM, Pereyre S. Mechanisms of drug resistance in Mycoplasma pneumoniae. Curr Drug Targets Infect Disord. 2005;5:263–71.

pubmed: 16181145 doi: 10.2174/1568005054880109

Pereyre S, Goret J, Bebear C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol. 2016;7:974.

pubmed: 27446015 pmcid: 4916212 doi: 10.3389/fmicb.2016.00974

Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother. 2004;48:4624–30.

pubmed: 15561835 pmcid: 529214 doi: 10.1128/AAC.48.12.4624-4630.2004

Li SL, Sun HM, Zhu BL, Liu F, Zhao HQ. Whole genome analysis reveals new insights into macrolide resistance in Mycoplasma pneumoniae. Biomed Environ Sci. 2017;30:343–50.

pubmed: 28549490

Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother. 2010;16:78–86.

pubmed: 20094751 doi: 10.1007/s10156-009-0021-4

van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis. 2008;14:1722–30.

pubmed: 18976555 pmcid: 2630720 doi: 10.3201/eid1411.070467

Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32:956–73.

pubmed: 18754792 doi: 10.1111/j.1574-6976.2008.00129.x

Zhao F, Liu J, Shi W, Huang F, Liu L, Zhao S, et al. Antimicrobial susceptibility and genotyping of Mycoplasma pneumoniae isolates in Beijing, China, from 2014 to 2016. Antimicrob Resist Infect Control. 2019;8:18.

pubmed: 30697421 pmcid: 6346583 doi: 10.1186/s13756-019-0469-7

Zhao F, Li J, Liu J, Guan X, Gong J, Liu L, et al. Antimicrobial susceptibility and molecular characteristics of Mycoplasma pneumoniae isolates across different regions of China. Antimicrob Resist Infect Control. 2019;8:143.

pubmed: 31463046 pmcid: 6708159 doi: 10.1186/s13756-019-0576-5

Wang N, Zhang H, Yin Y, Xu X, Xiao L, Liu Y. Antimicrobial susceptibility profiles and genetic characteristics of Mycoplasma pneumoniae in Shanghai, China, from 2017 to 2019. Infect Drug Resist. 2022;15:4443–52.

pubmed: 35983294 pmcid: 9379117 doi: 10.2147/IDR.S370126

Oishi T, Takahashi K, Wakabayashi S, Nakamura Y, Ono S, Kono M, et al. Comparing antimicrobial susceptibilities among Mycoplasma pneumoniae isolates from pediatric patients in Japan between two recent epidemic periods. Antimicrob Agents Chemother. 2019;63:e02517–8.

pubmed: 31010867 pmcid: 6591619 doi: 10.1128/AAC.02517-18

Oishi TYD, Nakano T, Ouchi K. Recent trend of antimicrobial susceptibility among M. pneumoniae isolated from Japanese Children. Microorganisms. 2022;10:2428.

pubmed: 36557681 pmcid: 9787913 doi: 10.3390/microorganisms10122428

Xiao L, Ratliff AE, Crabb DM, Mixon E, Qin X, Selvarangan R, et al. Molecular characterization of Mycoplasma pneumoniae isolates in the United States from 2012 to 2018. J Clin Microbiol. 2020;58:e00710–20.

pubmed: 32817226 pmcid: 7512161 doi: 10.1128/JCM.00710-20

Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006;50:709–12.

pubmed: 16436730 pmcid: 1366908 doi: 10.1128/AAC.50.2.709-712.2006

Xin DL, Wang S, Han X, Ma SJ, Chen XG. Clinical characteristics of children with drug-resistant pneumonia mycoplasma pneumonia. Chin J Appl Clin Pediatr. 2010;25:1213–5 (in Chinese).

Ma Z, Zheng Y, Deng J, Ma X, Liu H. Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen. China Pediatr Pulmonol. 2014;49:695–700.

pubmed: 23861188 doi: 10.1002/ppul.22851

Yoon IA, Hong KB, Lee HJ, Yun KW, Park JY, Choi YH, et al. Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2017;17:402.

pubmed: 28592263 pmcid: 5463359 doi: 10.1186/s12879-017-2500-z

Matsubara K, Morozumi M, Okada T, Matsushima T, Komiyama O, Shoji M, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother. 2009;15:380–3.

pubmed: 20012728 doi: 10.1007/s10156-009-0715-7

Seo YH, Kim JS, Seo SC, Seo WH, Yoo Y, Song DJ, et al. Predictive value of C-reactive protein in response to macrolides in children with macrolide-resistant Mycoplasma pneumoniae pneumonia. Korean J Pediatr. 2014;57:186–92.

pubmed: 24868216 pmcid: 4030120 doi: 10.3345/kjp.2014.57.4.186

Wu PS, Chang LY, Lin HC, Chi H, Hsieh YC, Huang YC, et al. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan Province of China. Pediatr Pulmonol. 2013;48:904–11.

pubmed: 23169584 doi: 10.1002/ppul.22706

Kuo CY, Tsai WC, Lee HF, Ho TS, Huang LM, Shen CF, et al. The epidemiology, clinical characteristics, and macrolide susceptibility of Mycoplasma pneumoniae pneumonia in children in Southern Taiwan Province of China, 2019–2020. J Microbiol Immunol Infect. 2022;55:611–9.

pubmed: 34688576 doi: 10.1016/j.jmii.2021.09.010

Zhou Y, Zhang Y, Sheng Y, Zhang L, Shen Z, Chen Z. More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother. 2014;58:1034–8.

pubmed: 24277047 pmcid: 3910883 doi: 10.1128/AAC.01806-13

Kim YJ, Shin KS, Lee KH, Kim YR, Choi JH. Clinical characteristics of macrolide-resistant Mycoplasma pneumoniae from Children in Jeju. J Korean Med Sci. 2017;32:1642–6.

pubmed: 28875608 pmcid: 5592178 doi: 10.3346/jkms.2017.32.10.1642

Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2008;52:348–50.

pubmed: 17954691 doi: 10.1128/AAC.00779-07

Lee E, Cho HJ, Hong SJ, Lee J, Sung H, Yu J. Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children. Korean J Pediatr. 2017;60:151–7.

pubmed: 28592978 pmcid: 5461279 doi: 10.3345/kjp.2017.60.5.151

Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother. 2013;57:2252–8.

pubmed: 23459497 pmcid: 3632908 doi: 10.1128/AAC.00048-13

National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2023 edition). Chin J Rational Drug Use. 2023;20:16–24 (in Chinese).

Narita M, Tanaka H. Late increase of interleukin-18 levels in blood during Mycoplasma pneumoniae pneumonia. Cytokine. 2012;59:18–9.

pubmed: 22564533 doi: 10.1016/j.cyto.2012.04.007

Chen Y, Tian WM, Chen Q, Zhao HY, Huang P, Lin ZQ, et al. Clinical characteristics and treatment of children with Mycoplasma pneumoniae with macrolide-resistant drugs. Chin J Contemp Pediatr. 2018;20:629–34 (in Chinese).

Matsuda K, Narita M, Sera N, Maeda E, Yoshitomi H, Ohya H, et al. Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan. BMC Infect Dis. 2013;13:591.

pubmed: 24330612 pmcid: 3883477 doi: 10.1186/1471-2334-13-591

Wu TH, Wang NM, Liu FC, Pan HH, Huang FL, Fang YP, et al. Macrolide resistance, clinical features, and cytokine profiles in Taiwanese children with Mycoplasma pneumoniae infection. Open Forum Infect Dis. 2021;8:ofab416.

pubmed: 34557557 pmcid: 8454522 doi: 10.1093/ofid/ofab416

Chen JY, Zhang H, Shang YX. Clinical and bronchoscopic characteristics of children with 23S rRNA resistance gene in Mycoplasma pneumoniae bronchoalveolar lavage fluid. Chin J Appl Clin Pediatr. 2022;37:897–902 (in Chinese).

Zhang YJ, Meng C. Mutation analysis of mycoplasma macrolide drug resistance gene in children with refractory pneumonia in children. Chin J Pract Pediatr. 2023;38:376–80 (in Chinese).

Morozumi M, Hasegawa K, Chiba N, Iwata S, Kawamura N, Kuroki H, et al. Application of PCR for Mycoplasma pneumoniae detection in children with community-acquired pneumonia. J Infect Chemother. 2004;10:274–9.

pubmed: 16163461 doi: 10.1007/s10156-004-0338-Y

Dorigo-Zetsma JW, Zaat SA, Wertheim-van Dillen PM, Spanjaard L, Rijntjes J, van Waveren G, et al. Comparison of PCR, culture, and serological tests for diagnosis of Mycoplasma pneumoniae respiratory tract infection in children. J Clin Microbiol. 1999;37:14–7.

pubmed: 9854056 pmcid: 84154 doi: 10.1128/JCM.37.1.14-17.1999

Ieven M, Ursi D, Van Bever H, Quint W, Niesters HG, Goossens H. Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. J Infect Dis. 1996;173:1445–52.

pubmed: 8648218 doi: 10.1093/infdis/173.6.1445

Peuchant O, Menard A, Renaudin H, Morozumi M, Ubukata K, Bebear CM, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother. 2009;64:52–8.

pubmed: 19429926 doi: 10.1093/jac/dkp160

Liu Y, Ye X, Zhang H, Wu Z, Xu X. Rapid detection of Mycoplasma pneumoniae and its macrolide-resistance mutation by Cycleave PCR. Diagn Microbiol Infect Dis. 2014;78:333–7.

pubmed: 24503503 doi: 10.1016/j.diagmicrobio.2013.12.002

Ji M, Lee NS, Oh JM, Jo JY, Choi EH, Yoo SJ, et al. Single-nucleotide polymorphism PCR for the detection of Mycoplasma pneumoniae and determination of macrolide resistance in respiratory samples. J Microbiol Methods. 2014;102:32–6.

pubmed: 24780151 doi: 10.1016/j.mimet.2014.04.009

Wagner K, Imkamp F, Pires VP, Keller PM. Evaluation of lightmix Mycoplasma macrolide assay for detection of macrolide-resistant Mycoplasma pneumoniae in pneumonia patients. Clin Microbiol Infect. 2019;25:e5–7.

Morinaga Y, Suzuki H, Notake S, Mizusaka T, Uemura K, Otomo S, et al. Evaluation of GENECUBE Mycoplasma for the detection of macrolide-resistant Mycoplasma pneumoniae. J Med Microbiol. 2020;69:1346–50.

pubmed: 33141009 doi: 10.1099/jmm.0.001264

Kakiuchi T, Miyata I, Kimura R, Shimomura G, Shimomura K, Yamaguchi S, et al. Clinical evaluation of a novel point-of-care assay to detect Mycoplasma pneumoniae and associated macrolide-resistant mutations. J Clin Microbiol. 2021;59:e0324520.

pubmed: 33910960 doi: 10.1128/JCM.03245-20

Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev. 2015;1:CD004875.

pubmed: 25566754

Yamazaki T, Kenri T. Epidemiology of M. pneumoniae Infections in Japan and therapeutic strategies for macrolide-resistant Mycoplasma pneumoniae. Front Microbiol. 2016;7:693.

pubmed: 27242718 pmcid: 4876131 doi: 10.3389/fmicb.2016.00693

Chou CC, Shen CF, Chen SJ, Chen HM, Wang YC, Chang WS, et al. Recommendations and guidelines for the treatment of pneumonia in Taiwan Province of China. J Microbiol Immunol Infect. 2019;52:172–99.

pubmed: 30612923 doi: 10.1016/j.jmii.2018.11.004

Ishiwada N, Shinjoh M, Kusama Y, Arakawa H, Ohishi T, Saitoh A, et al. Guidelines for the management of respiratory infectious diseases in children in Japan 2022. Pediatr Infect Dis J. 2023;42:e369–76.

pubmed: 37566891 doi: 10.1097/INF.0000000000004041

Ishiguro N, Koseki N, Kaiho M, Ariga T, Kikuta H, Togashi T, et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. PLoS One. 2017;12:e0173635.

pubmed: 28288170 pmcid: 5348022 doi: 10.1371/journal.pone.0173635

Ahn JG, Cho HK, Li D, Choi M, Lee J, Eun BW, et al. Efficacy of tetracyclines and fluoroquinolones for the treatment of macrolide-refractory Mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis. BMC Infect Dis. 2021;21:1003.

pubmed: 34563128 pmcid: 8465761 doi: 10.1186/s12879-021-06508-7

Wu JY, Sun SM. Expert consensus on the application of fluoroquinolones antibacterial drugs in children. Pharmacy Today. 2018;28:1–10 (in Chinese).

Okubo Y, Michihata N, Morisaki N, Uda K, Miyairi I, Ogawa Y, et al. Recent trends in practice patterns and impact of corticosteroid use on pediatric Mycoplasma pneumoniae-related respiratory infections. Respir Investig. 2018;56:158–65.

pubmed: 29548654 doi: 10.1016/j.resinv.2017.11.005

Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood—time to rebuild its reputation? Expert Opin Drug Saf. 2016;15:367–82.

pubmed: 26680308 pmcid: 4898140 doi: 10.1517/14740338.2016.1133584

Poyhonen H, Nurmi M, Peltola V, Alaluusua S, Ruuskanen O, Lahdesmaki T. Dental staining after doxycycline use in children. J Antimicrob Chemother. 2017;72:2887–90.

pubmed: 29091225 pmcid: 5890778 doi: 10.1093/jac/dkx245

Editing Group for Multidisciplinary Expert Consensus on the Rational Use of Tetracyclines Commonly Used in Clinical Practice, Hospital Infection Control Branch of Chinese Preventive Medicine Association, Clinical Pharmacology Branch of Chinese Pharmacological Society. Multidisciplinary expert consensus on the rational use of tetracyclines commonly used in clinical practice. Zhonghua Yi Xue Za Zhi. 2023;103:2281–96 (in Chinese).

Qiu JL, Huang L, Shao MY, Chai YN, Zhang HJ, Li XF, et al. Efficacy and safety of azithromycin combined with glucocorticoid on refractory Mycoplasma pneumoniae pneumonia in children: a PRISMA-compliant systematic review and meta-analysis. Medicine. 2020;99:e20121.

pubmed: 32481378 doi: 10.1097/MD.0000000000020121

Kim HS, Sol IS, Li D, Choi M, Choi YJ, Lee KS, et al. Efficacy of glucocorticoids for the treatment of macrolide refractory Mycoplasma pneumoniae in children: meta-analysis of randomized controlled trials. BMC Pulm Med. 2019;19:251.

pubmed: 31852460 pmcid: 6921474 doi: 10.1186/s12890-019-0990-8

Sun LL, Ye C, Zhou YL, Zuo SR, Deng ZZ, Wang CJ. Meta-analysis of the clinical efficacy and safety of high- and low-dose methylprednisolone in the treatment of children with severe Mycoplasma pneumoniae pneumonia. Pediatr Infect Dis J. 2020;39:177–83.

pubmed: 31738328 doi: 10.1097/INF.0000000000002529

Chen LL, Liu JR, Zhao SY, Yang YG, Wu JZ. Clinical features and treatment of refractory Mycoplasma pneumoniae pneumonia unresponded to conventional dose methylprednisolone in children. Zhonghua Er Ke Za Zhi. 2014;53:172–6 (in Chinese).

Shen KL, Deng L, Li YZ, Li CC, Xiang L, Liu EM, et al. Expert consensus on the application of glucocorticoid atomization inhalation therapy in pediatrics (2018 revision). J Clin Pediatr. 2018;36:95–107 (in Chinese).

Expert Group of Pediatric Respiratory Endoscopy Diagnosis and Treatment Technology Project of the Talent Exchange Service Center of the National Health Commission, Pediatric Respiratory Endoscopy Professional Committee of the Endoscopy Branch of the Chinese Medical Association. The consensus of experts on the interventional diagnosis and treatment of refractory pneumonia in Chinese children. Chin J Pract Pediatr. 2019;34:449–57 (in Chinese).

Shi DW, Liu L, Zhao MM, Ye LP, Zhou W, Guo DX, et al. Analysis of drug resistance gene in Mycoplasma pneumoniae and 13 pathogens in bronchoalveolar lavage fluid of children with Mycoplasma pneumoniae pneumonia. Chin J Appl Clin Pediatr. 2022;37:893–6 (in Chinese).

Wang L, Xie Q, Xu S, Li H, Zhang L, Ai J, et al. The role of flexible bronchoscopy in children with Mycoplasma pneumoniae pneumonia. Pediatr Res. 2023;93:198–206.

pubmed: 35459766 doi: 10.1038/s41390-021-01874-z

Lv LY, Yang LP, Wang LW, Wan NJ, Zhu YL, Zhu RN, et al. Twenty-six cases of mycoplasma of central nervous system pneumonia in children. Chin J Appl Clin Pediatr. 2009;24:763–4 (in Chinese).

Gu JL, Lu ZW, Wang WJ, Zheng YJ, Li J, Shao YB. 11 cases of Mycoplasma pneumoniae-associated hemophagocytic syndrome: a case series report. Chin J Evid Based Pediatr. 2020;15(3):229–32 (in Chinese).

Chen N, Li M. Case report and literature review: clinical characteristics of 10 children with Mycoplasma pneumoniae-induced rash and mucositis. Front Pediatr. 2022;10:823376.

pubmed: 35311047 pmcid: 8927760 doi: 10.3389/fped.2022.823376

Shan LS, Liu X, Kang XY, Wang F, Han XH, Shang YX. Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children. World J Pediatr. 2017;13:321–7.

pubmed: 28130749 doi: 10.1007/s12519-017-0014-9